Pharmaceutical

Risk adjusted net present value: What is the current valuation of AbbVie’s ABBV-400?

ABBV-400 is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase II program in Metastatic Colorectal Cancer.

Apr 17, 2024 - 00:00
ABBV-400 is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase II program in Metastatic Colorectal Cancer.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Merck’s MK-1084?

Next Article

Risk adjusted net present value: What is the current valuation of AstraZeneca’s ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: One dose of psilocybin may have lasting effects on major depression, study finds

STAT+: One dose of psilocybin may have lasting effects ...

Aug 31, 2023

STAT+: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs

STAT+: Novo Nordisk enlists two Flagship biotechs to de...

Jan 4, 2024

Why many more people are lining up for a flu shot than a Covid vaccine

Why many more people are lining up for a flu shot than ...

Jan 22, 2024